Guo Meng-Qin, Hu Ping, Huang Zheng-Wei
College of Pharmacy, Jinan University, Guangzhou 511443, Guangdong Province, China.
World J Stem Cells. 2025 Mar 26;17(3):101376. doi: 10.4252/wjsc.v17.i3.101376.
Xiao reported on the natural product sinomenine (SIN), which is a traditional Chinese medicine for treating osteoporosis its modulation of autophagy; however, SIN was dissolved in dimethyl sulfoxide prior to administration, which is not conducive to the development of clinical injectables. By comparing solubilization techniques, including amorphisation, emulsification, micellisation, nano-crystallisation and host-guest inclusion, we found that the solubilization of SIN by host-guest inclusion can enhance solubility and improve stability and has an increased release rate and enhanced bioavailability. Therefore, we conclude that host-guest inclusion holds promise for SIN solubilization. To solubilise SIN, we selected β-cyclodextrin as the host agent considering its excellent biocompatibility, efficient encapsulation ability, mature preparation process and adequate drug stability. If the prerequisites of SIN-β-cyclodextrin complexes in terms of safety, efficacy, stability and the relevant laws and regulations are met, its clinical application for the treatment of osteoporosis may be achieved.
肖报道了天然产物青藤碱(SIN),它是一种治疗骨质疏松症的传统中药及其对自噬的调节作用;然而,SIN在给药前溶解于二甲基亚砜中,这不利于临床注射剂的开发。通过比较包括无定形化、乳化、胶束化、纳米结晶和主客体包合等增溶技术,我们发现主客体包合对SIN的增溶可提高其溶解度、改善稳定性、增加释放速率并提高生物利用度。因此,我们得出结论,主客体包合有望用于SIN的增溶。为了增溶SIN,我们选择β-环糊精作为主体试剂,考虑到其优异的生物相容性、高效的包封能力、成熟的制备工艺和足够的药物稳定性。如果SIN-β-环糊精复合物在安全性、有效性、稳定性及相关法律法规方面的前提条件得到满足,其在治疗骨质疏松症方面的临床应用可能会实现。